Aurobindo Pharma receives USFDA approval for Metronidazole Tablets USP

01 Jun 2015 Evaluate

Aurobindo Pharma has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Metronidazole Tablets USP 250mg and 500mg (ANDA 203974). The company will commence shipping shortly. The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Flagyl Tablets, 250mg and 500mg of GD Searle LLC.

Metronidazole Tablets are used to treat different types of infections which are due to particular types of bacteria and some other infectious organisms, or to prevent infection during an operation. The product has an estimated market size of $58 Million for the twelve months ending March 2015 according to IMS.

This is the 37th ANDA to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-betalactam products. Aurobindo now has a total of 194 ANDA approvals (167 Final approvals including 9 from Aurolife Pharma LLC and 27 Tentative approvals) from USFDA.

Aurobindo Pharma Share Price

1156.95 -11.95 (-1.02%)
02-Feb-2026 11:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1602.00
Dr. Reddys Lab 1170.25
Cipla 1293.60
Zydus Lifesciences 866.50
Lupin 2082.55
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×